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A B S T R A C T
Objective: Methamphetamine dependence can lead to psychotic symptoms which may be mediated by frontal,
striatal, limbic, and thalamic regions. There are few neuroimaging data that allow comparison of individuals
with methamphetamine dependence who do, and do not, have psychosis. Two complementary imaging tech-
niques were employed to investigate neurocircuitry associated with methamphetamine dependence with and
without psychotic symptoms.
Methods: Three groups of participants were recruited: methamphetamine dependent (MAA) (N=11), me-
thamphetamine dependent with psychotic symptoms (MAP) (N=14), and controls (N=14). Resting brain
glucose metabolism was measured using [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET)
and cerebral perfusion was assessed using arterial spin labelling (ASL) magnetic resonance imaging.
Results: Methamphetamine abusers (MAA and MAP groups) had decreased glucose metabolism compared to
healthy controls in the left insula, left precentral gyrus, and the anterior cingulate cortex. Compared to MAA
participants, MAP participants had 1) decreased glucose metabolism in the left precentral gyrus and the left
inferior frontal gyrus and 2) increased glucose metabolism in the putamen and pallidum. MAP participants also
had increased cerebral perfusion in the right putamen and right pallidum compared to MAA.
Conclusion: Findings support the involvement of frontal, striatal, and limbic regions in methamphetamine de-
pendence. Furthermore, they indicate that glucose metabolism and cerebral perfusion in these regions are dis-
rupted in methamphetamine dependent individuals with psychotic symptoms.
1. Introduction
Methamphetamine (MA) abuse has been of particular concern for a
number of reasons including its association with the psychotic disorder
methamphetamine-associated psychosis (MAP) (Connell, 1958; Angrist
and Gershon, 1970; Bell, 1973), which may be mediated by frontal,
striatal, limbic, and thalamic regions (Hsieh et al., 2014). Fortunately,
brain imaging research has advanced our understanding of the neuro-
circuitry and neurochemistry of methamphetamine dependence and
MAP. In vivo human studies using positron emission tomography (PET)
and magnetic resonance imaging (MRI) to investigate MA-associated
neurotoxicity have shown reduced density of dopaminergic markers
such as D2 receptors (Volkow et al., 2001b), dopamine transporters
(DAT) (Volkow et al., 2001c; Sekine et al., 2003) and vesicular mono-
amine transporter-2 (Johanson et al., 2006), as well as reduced density
of serotonin transporters (Sekine et al., 2006).
Human studies using [18F]fluorodeoxyglucose (FDG) PET have in-
vestigated global and regional cerebral glucose metabolism in MA
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abuse (Volkow et al., 2001a; London et al., 2004, 2005; Wang et al.,
2004; Kim et al., 2005, 2009). Cerebral glucose metabolism serves as a
marker of neuronal activity (Schmidt et al., 1996) and is altered in drug
addiction (reviewed in Gatley and Volkow, 1998; Volkow et al., 2001a).
Studies by both Volkow et al. (2001a, b, c) as well as Wang et al. (2004)
show decreases in both striatal and thalamic glucose metabolism in MA
abusers compared to healthy controls. Other studies have reported
decreased cerebral glucose metabolism in the anterior cingulate cortex
(ACC) of individuals with MA abuse when compared to controls
(London et al., 2004, 2005). There are, however, no FDG PET data that
allow comparison of methamphetamine dependence with and without
psychosis.
Studies show that although a large majority of the symptoms of MA-
induced psychosis resolve within 1month (Iwanami et al., 1994; Deng
et al., 2012), some may persist for 6months (Deng et al., 2012), and
others for even> 6months (Iwanami et al., 1994; Deng et al., 2012).
There are also reports of symptoms reoccurring after long periods of
abstinence (Yui et al., 1997, 1999). MA-induced psychosis presents
clinically similarly to acute paranoid schizophrena. Some of the most
thoroughly investigated regions with alterations in schizophrenia in-
clude the cerebral cortex, hippocampus and basal ganglia (structures
include the putamen and pallidum). Due to the considerable diversity of
symptoms in schizophrenia, it is widely accepted that impairments are
not localized to specific regions, but rather involve the disruption of
several regions. Studies looking at active psychosis in Alzheimer's dis-
ease and schizophrenia showed decreased cerebral glucose metabolism
in the orbitofrontal cortex (OFC) (Koppel et al., 2014), and increases in
medial temporal regions, basal ganglia, and left thalamic regions, with
decreases in the cerebellum (Seethalakshmi et al., 2006).
Arterial spin labeling (ASL) is a MRI technique which uses magne-
tically tagged blood as a tracer, and is also used to measure regional
cerebral blood flow (rCBF) (Théberge, 2008). As with FDG PET studies,
ASL studies, in humans, include those examining schizophrenia
(Federspiel et al., 2004; Kindler et al., 2015). Under normal, standard
conditions, glucose metabolism and blood flow are tightly coupled. We
would therefore expect perfusion findings to reflect the findings from
PET (Raichle et al., 2001; Vaishnavi et al., 2010). The only study – to
our knowledge – looking at cerebral perfusion in MA dependence is that
by Chang et al. (2002) who used a contrast agent. They found MA to
have a decreased rCBF bilaterally in the putamen/insular cortex and in
a right lateral parietal brain region, and increased rCBF bilaterally in
left temporoparietal white matter (WM), and in left occipital, and right
posterior parietal regions.
FDG is a glucose analogue, and FDG uptake is related to glucose
metabolism, albeit in a non-linear way. ASL allows examination of re-
gional cerebral blood flow. Looking at two complementary imaging
techniques measuring CBF and glucose metabolism may provide in-
sights into the neural mechanisms underlying these MA-associated
pathologies. Therefore, this study examined the differences in cerebral
glucose metabolism (using FDG-PET) and rCBF (with ASL) between MA
and healthy controls; moreover, these variables were compared be-
tween MA with and without psychosis.
2. Methods and materials
2.1. Participants
Three groups (MA dependent, MA dependent with psychotic
symptoms, and healthy controls (HC) were recruited and underwent
imaging with both PET and MRI (see Tables 1 and 2). The MA depen-
dent participants without psychotic symptoms (MAA) were recruited
from local rehabilitation and drug counselling centers, and the parti-
cipants with MA dependence with psychotic symptoms (MAP) were
recruited from a local psychiatric hospital. Controls were recruited from
the same communities as the MA dependent participants. All 3 groups
were matched in terms of age and education, and the MA dependent
and MAP groups were matched in terms of age of first use, duration of
use, and the time since last use. Thirty-nine participants were enrolled
in total.
After initial telephonic or face-to-face screening, potential partici-
pants underwent a Structured Clinical Interview (SCID) for the DSM-IV.
Written informed consent was obtained after the study procedures were
explained. Participants were included in the study if they were between
18 and 40 years old. Both MA dependent groups were required to have
a lifetime diagnosis of MA-dependence on the SCID in accordance with
the DSM-IV, be currently drug abstinent (at least 7 days), but have used
MA in the previous 6months. The MAP group were required to have
had a history of experiencing psychotic symptoms lasting for at least
one week in total and associated with MA use. Psychotic symptoms
were defined as a minimum score of 3 or more on any one of the items
P1, P2, P3, and G9 of the Positive and Negative Syndrome Scale
(PANSS) rating scale. In all cases, psychotic symptoms induced by MA
persisted to the extent that patients required extended hospitalization.
However, where psychotic symptoms persisted for so long that the di-
agnosis was uncertain, or changed to schizophrenia, for example, they
were excluded.
Exclusion criteria for all groups included substance-dependence
other than MA (except nicotine and marijuana), lifetime and current
diagnosis of psychiatric disorders (with the exception of psychosis for
the MAP group), history of psychosis prior to MA-use, medical or
neurological illness or trauma that would affect the central nervous
system, a reported history of a seropositive test for HIV (assessed by
self-report) – HIV infection has been associated with changes in brain
morphology (Jernigan et al., 2005), severe renal, hepatic, pulmonary,
or endocrine disease, head injury resulting in unconsciousness, any
metal implantation that would preclude MRI, known claustrophobia or
intolerance for confined spaces or previous intolerance of examination
in a scanner, intoxication or withdrawal delirium, pregnancy or
Table 1
Characteristics of participants included across both modalities.
Participant group
Variables HC MAA MAP p value
Number (n) 14 11 14 –
Males 7 5 9 0.6
Age, years 26.3 (4.7) 29 (4.2) 26.1 (6) 0.2
Education, years 11.5 (1.1) 10.6 (2) 10.4 (2.6) 0.1
Age of first MA-use, years – 18.2 (7.6) 18.2 (6.9) 0.9
Duration of use, years – 8 (4.6) 7.9 (4.7) 0.1
Time since last use, days – 39.6 (21.2) 37.6 (19.7) 0.5
Abbreviations: MA, methamphetamine; HC, healthy controls; MAA, metham-
phetamine abusers; MAP, methamphetamine abusers with psychotic symptoms;
M, male participants; Data shown as mean values (standard deviation); p value
for the statistical tests: Chi-Square test for gender distribution (across 3 groups),
one-way ANOVA for age and education (across 3 groups) and Student two-
sample t-test (unequal variance assumed) for the drug use measures (MAA vs
MAP).
Table 2
Participants included in each of the modalities.
Modality
FDG PET (n=33) ASL MRI (n=31)
HC MAA MAP HC MAA MAP
Number of participants 11 10 12 11 9 11
Gender (M/F) 6/5 5/5 7/5 7/4 4/5 6/5
Abbreviations: HC, healthy controls; MAA, methamphetamine abusers; MAP,
methamphetamine abusers with psychotic symptoms; M, male participants; F,
female participants.
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breastfeeding, diabetes, lack of fluency in English, and left-handedness.
Urine screens were performed on both scanning days to verify MA
abstinence as well as for a pregnancy test for female participants in all 3
groups. Substance use measures in the MA groups included life-time use
of all major drug types, and days of drug use in the past month by drug
type. Measures of MA-use included age of first MA-use, frequency and
quantity of MA-use in the past year, and the number of drug-free days
prior to scanning. The duration of time on neuroleptic agents for the
MAP group was recorded. The study was approved by the Health Re-
search Ethics Committees of both the University of Cape Town and
Stellenbosch University.
2.2. Image acquisition
The PET scanning took place at the Western Cape Academic PET/CT
Centre at Tygerberg Hospital. PET scans were acquired using a Phillips
Gemini TF Big Bore scanner (Phillips Medical Systems). All PET ac-
quisitions were conducted at a similar time of day in order to minimize
variations in diurnal patterns of cortisol. On the day of the scan, par-
ticipants were required to fast for 4–6 h prior to the scan, although
intake of plain water was encouraged. PET imaging was performed
30min after the intravenous administration of a dose of 150MBq of
FDG. Scanning was done with the subject's head supported by a
headrest and bandage. To correct for attenuation, a low-dose CT was
performed without contrast (120 kV tube potential, 20 mAs). This was
followed by a 30-min dynamic acquisition of emission data. Data were
rebinned as 15 2-min scans, after reconstructing using 3D line of re-
sponse row-action maximum likelihood algorithm (LOR-RAMLA).
Corrections for scatter, random events and attenuation were included.
The reconstructed images were comprised of 90 slices covering the
whole brain (voxel size= 2×2×2 mm3).
The MRI scanning took place within 24 h of the PET scan at ap-
proximately the same time of day. Scanning was conducted using a 3T
Siemens Magnetom Allegra at CUBIC (Cape Universities Brain Imaging
Centre) in Tygerberg. The following images were acquired: 1) a high
resolution T1-weighted 3D anatomical image (MPRAGE): sagittal or-
ientation, 160 slices, TR= 2530ms, TE=1.53, 3.21, 4.89, 6.57ms,
240×256 matrix, voxel size= 1×1×1mm3, flip angle= 7 degrees;
and 2) pseudo continuous arterial spin labelling (pCASL): eyes closed:
scan time=8min, TR=3300ms, TE= 16ms, flip angle= 90 de-
grees, voxel size= 3.6× 3.6× 5mm3, 64× 64 matrix.
2.3. Image and data analysis
Statistical Parametric Mapping software (SPM; version SPM8;
http://www.fil.ion.ucl.ac.uk/spm) and statistical non-parametric map-
ping software (SnPM; version SnPM13; http://warwick.ac.uk/snpm)
were used to perform all the analyses across both imaging techniques.
First, SPM8 was used to segment the MPRAGE into gray matter (GM),
white matter (WM) and cerebrospinal fluid (CSF). The segmentation
step also determined the transformation to MNI (Montreal Neurological
Institute) space. PET images were realigned to correct for small patient
movements and a summed image was created. Head movement was
considered to be excessive if scan-to-scan displacement was>2mm,
overall translation in any direction was> 5mm, or overall rotation in
any direction was> 3 degrees. If patient movement was excessive, the
summed image was limited to that part of the acquisition when
movement was considered acceptable (a minimum of 2 consecutive
volumes). The summed image was coregistered to the MPRAGE image
and the transformation to MNI was applied. PET images were smoothed
with a 12mm full width at half maximum (FWHM) isotropic 3-di-
mensional Gaussian kernel.
The ASL toolbox (Wang et al., 2008) (https://cfn.upenn.edu/
~zewang/ASLtbx.php) for SPM was used to perform the ASL analysis.
Pre-processing of the ASL data included realignment of the tag and
control images to correct for small head movements, coregistration of
tag/control images to the structural image (MPRAGE), followed by
smoothing with an 8mm FWHM Gaussian isotropic 3D kernel. For each
subject 60 consecutive volumes were selected, which minimized both
total range of motion and scan-to-scan motion. The participant was
eliminated if there was no segment of 60 consecutive volumes where
total range of motion was<1mm and scan-to-scan motion< 0.6mm.
CBF/perfusion images were calculated from each tag and control pair
using simple subtraction and using the mean of the control images as an
estimate of the equilibrium magnetization of blood. The mean CBF over
the whole brain was then checked, and any participants with a mean
CBF that was unrealistically low (< 20mL/min per 100 g) were ex-
cluded. All CBF functional images were warped to MNI (using the
transformation based on the MRPAGE).
2.4. Statistical analysis
We performed a voxel-based whole-brain analysis using statistical
non-parametric mapping (SnPM13) in which we compared regional
cerebral metabolic rate of glucose (using the FDG-PET images) or re-
gional cerebral blood flow (using the ASL images) in the healthy control
group and the patient group (the MAA and MAP group combined). We
used proportional scaling to normalize the image intensities. Next, we
did a similar analysis in which we compared the methamphetamine
abusers with and without psychotic symptoms. In all voxel- based
analyses, we considered a cluster to be significant when the cluster size
was significant at FWE corrected p < 0.05 with an initial uncorrected
voxel level threshold p < 0.001.
3. Results
3.1. Subjects
Thirty-nine participants underwent scanning. Characteristics of the
participants are given in Table 1. Participants were predominantly of
mixed ancestry in all groups and the primary route of administration for
all participants was smoking. Not all imaging sessions were successful
for every participant (e.g. technical reasons, movement in scanner, in-
complete scanning session), however the characteristics were not dif-
ferent between the remaining participants of each group (all p > 0.2)
(see supplementary material S1 and S2). Participants included in the
analysis for each imaging modality are shown in Table 2.
3.2. Cerebral metabolism
Analysis of PET data showed significantly decreased glucose meta-
bolism in the methamphetamine abusers (MAA and MAP group) com-
pared to healthy controls in the left insula, left precentral gyrus and the
anterior cingulate cortex (ACC) (Table 3. Fig. 1).
Table 3
Decreased regional cerebral glucose metabolism in methamphetamine abusers
(MAA and MAP group) compared to healthy controls. Local maxima of the







T X Y Z Anatomical
localization
0.047 652 0.006 6.25 −44 6 2 Left insula
0.100 4.87 −54 4 20 Left precentral
gyrus
0.016 1164 0.035 5.38 −4 40 12 Left anterior
cingulate
0.121 4.76 12 44 12 Right anterior
cingulate
Abbreviations: HC: healthy controls; MAA: methamphetamine abusers without
psychotic symptoms; MAP: methamphetamine abusers with psychotic symp-
toms.
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3.3. HC vs methamphetamine abusers
When comparing the methamphetamine abusers with and without
psychotic symptoms, we found increased cerebral metabolism in MAA
compared to MAP in the left precentral gyrus and the left inferior
frontal gyrus, and decreased metabolism in the putamen and the pal-
lidum (Table 4, Fig. 2).
3.4. Cerebral perfusion
Analysis of ASL data showed no significant difference between the
healthy controls and the methamphetamine abusers (MAA and MAP
group). However, when comparing the methamphetamine abusers with
(MAP group) and without (MAA group) psychotic symptoms, we found
a decreased cerebral perfusion in the MAA group compared to the MAP
group in the right putamen and right pallidum (Table 5, Fig. 3).
4. Discussion
The main findings of this study were 1) Methamphetamine abusers
(MAA and MAP group) had decreased glucose metabolism compared to
healthy controls in the left insula, left precentral gyrus, and the anterior
cingulate cortex. 2) MAP participants had 2a) decreased glucose me-
tabolism in the left precentral gyrus and the left inferior frontal gyrus
and 2b) increased glucose metabolism in the putamen and pallidum
compared to MAA participants, and 3) Compared to MAA, MAP had
increased cerebral perfusion in the right putamen and right pallidum.
Results from the PET analysis are in line with findings from London
and colleagues who reported regions of decreased relative regional
cerebral glucose metabolism in MA-dependent individuals in the ACC
(London et al., 2004), which is involved in both cognitive and
Fig. 1. Significant decreased regional glucose metabolism in the MA depen-
dence groups (MAA and MAP) compared to the healthy control group shown in
red on three axial slices with the z-coordinate of the slice in MNI space on top.
The statistical map was thresholded using an uncorrected p < 0.001 at the
voxel level combined with an FWE-corrected p < 0.05 at the cluster level.
Images are displayed in neurological convention.
Table 4
Comparison of regional cerebral glucose metabolism in methamphetamine
abusers with and without psychotic symptoms. Local maxima of the statistical
non-parametric maps are given. X,Y,Z refer to MNI coordinates.




T X Y Z Anatomical
localization
MAA > MAP













0.022 876 0.030 6.06 −30
-12 0
Left putamen
0.039 631 0.040 5.91 30 -8 2 Right putamen
0.54 4.08 16 4 6 Right pallidum
Abbreviations: MAA: methamphetamine abusers without psychotic symptoms;
MAP: methamphetamine abusers with psychotic symptoms.
Fig. 2. Comparison of the MA-dependence groups with and without psychotic
symptoms. Group shown on a left sagittal slice at MNI coordinate x=−50 and
an axial slice at MNI coordinate z= 2. Decreases and increases in the MAP
group compared to the MAA group are shown in red and blue, respectively. The
statistical maps were thresholded using an uncorrected p < 0.001 at the voxel
level combined with a FWE-corrected p < 0.05 at the cluster level. Images are
displayed in neurological convention.
Table 5
Decreased regional cerebral blood flow in methamphetamine abusers without
psychotic symptoms compared to those with psychotic symptoms
(MAA < MAP). Local maxima of the statistical non-parametric maps are given.







T X Y Z Anatomical
localization
0.031 532 0.38 4.47 28 -10
12
Right putamen
0.57 4.09 20 -2 2 Right pallidum
Abbreviations: MAA: methamphetamine abusers without psychotic symptoms;
MAP: methamphetamine abusers with psychotic symptoms.
Fig. 3. Regions of significantly decreased regional cerebral perfusion in parti-
cipants with methamphetamine dependence without psychotic symptoms
compared to methamphetamine abusers with psychotic symptoms shown in
blue on axial slices at MNI coordinates z= 4 and 12. The statistical maps were
thresholded using an uncorrected p < 0.001 at the voxel level combined with
an FWE-corrected p < 0.05 at the cluster level. Images are displayed in neu-
rological convention.
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emotional processing (Bush et al., 2000), when compared to HC. The
current study also found decreased relative regional cerebral glucose
metabolism in the ACC in the MA abusers' group when compared to HC.
Decreased glucose metabolism was also shown in the left insula and
precentral gyrus. Deficits in brain structure in cortical regions – the
frontal cortex in particular – have been widely reported in MA users,
with associated signs of cognitive and behavioral dysfunction
(Goldstein and Volkow, 2002; London et al., 2015). These data further
emphasize the effects that MA-use may have in this region.
Decreased relative regional cerebral glucose metabolism in the left
precentral gyrus and left inferior frontal gyrus was shown in the MAP
group when compared to the MAA group.
Although no studies have looked specifically at MA psychosis within
these cortical regions, they have extensive connections. Evidence sug-
gests that the frontal regions are largely implicated in the pathogenesis
of psychotic disorders such as schizophrenia (Baker et al., 2014).
An increase in relative regional glucose metabolism in the putamen
and pallidum in the MAP group when compared to the MAA group was
shown in this study, and is in line with work by Seethalakshmi et al.
(2006), who showed increased glucose metabolism in the basal ganglia
in individuals with active psychosis in schizophrenia. These results
therefore seem to be specific to the psychotic group and include regions
that are increasingly present in recent work on schizophrenia. A mul-
ticenter large-scale meta-analysis of neuroimaging data of subcortical
brain abnormalities in schizophrenia, reported a larger pallidum in
schizophrenia (van Erp et al., 2016). This finding was replicated by
Okada and colleagues (Okada, 2016) who also showed asymmetries in
various subcortical brain volumes, including a leftward asymmetry in
the pallidum in schizophrenia patients when compared to HC. Given
that differences in glucose metabolism were seen between the me-
thamphetamine abuser groups in the current study, it suggests that
deficits in the respective regions specifically may be due to the devel-
opment of psychosis and not the use of MA.
The putamen and pallidum were also shown to have increased CBF
in MAP compared to MAA. Abnormalities such as enlarged volumes in
these structures have been shown to exist in schizophrenia (Hokama
et al., 1995). The current study showed increased regional cerebral
perfusion in subcortical structures. In contrast, ASL studies of poly-
substance abusers and cocaine abusers have shown decreased cortical
and subcortical CBF deficits, and cortical CBF deficits, respectively
(Murray et al., 2015; Gollub et al., 1998). Different substances of abuse
have their own individual mechanisms of action at specific sites, which
these results may reflect. As with an increased glucose metabolism in
the basal ganglia possibly contributing to psychosis, the same may
apply here with an increased CBF in the putamen and pallidum shown
in the MAP participants. Our results indicate partial but not complete
overlap of PET and ASL findings. A study by Cha et al. (2013) ex-
amining the correspondence between ASL and FDG-PET showed that –
although there was an overall good correlation between CBF, measured
by ASL, and glucose metabolism, measured by FDG-PET – there was
also regional variation. Interestingly, the highest correlation between
perfusion and metabolism was shown in the striatum.
Based on the considerable evidence implicating the involvement of
the putamen and pallidum in psychosis, and the finding that, in the
current study, differences were seen between the MAA and MAP
groups, the alterations in these regions may potentially be associated
with MA-induced psychosis; as a cause of the psychosis, or as a con-
sequence. Or, even as a compensatory effect.
Several limitations should be mentioned. It was not possible to
measure the quantity of MA used, as these data are unreliable due to the
fact participants bought the drug in “bags”, “packets”, “straws” or
“grams” and is thus a limitation of this study. The MAA patients may
have used less than the hospitalized MAP patients on average, which
would make this a confound. It was also not possible to measure and
compare the use of different substances across the groups due to un-
reliable drug histories and difficulty in quantifying amounts used. The
use of marijuana is a possible confounding factor of this study, given
that marijuana use has been associated with psychotic symptoms
(Arseneault et al., 2004). It should, however, be noted that all partici-
pants who used marijuana were only included if they met criteria for
“abuse”, and not “dependence”, according to the Structured Clinical
Interview for DSM-IV (SCID). All participants in the MAP group were
current inpatients at a psychiatric hospital, and were all receiving an-
tipsychotic medication. Participants in the MAA group were medica-
tion-free. While this is a potentially important confound, and it is
possible that some antipsychotics can affect brain perfusion
(Shcherbinin et al., 2015), there was no significant association between
duration of medication and glucose metabolism and cerebral perfusion
in the MAP group. This, however, could also be due to lack of statistical
power.
This is the first study to intensively study changes in brain meta-
bolism and blood flow in MAA and MAP compared to HC using PET and
ASL respectively and helps shed some light on the neurobiological
mechanisms underlying MA-use disorders. In particular, there is evi-
dence to further support the involvement of the ACC, insula and pre-
central gyrus in MA abuse, and disruption of the structures within the
basal ganglia in MA-dependent individuals with psychotic symptoms.
This is consistent with prior literature focusing on these regions in other
psychotic disorders, and with the hypothesis that methamphetamine-
induced psychosis serves as a model for schizophrenia (Hsieh et al.,
2014). By using multi-modal imaging, we have been able to find more
extensive changes than would have been detected with any single
modality. Further work, with specific radioligands to examine the
molecular neuroanatomy of MA-induced psychosis, and using larger
sample sizes, is needed to elucidate more fully the nature of these
changes. This may in turn ultimately facilitate correct diagnoses and
optimize therapeutic interventions.
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